Hejing Biotech (688068.SH): A total cost of 92.06 million yuan to buy back 3.14% of the shares

Gelonghui, April 16, 丨 Hot View Biotech (688068.SH) announced that by the close of trading on April 15, 2024, the company had repurchased 2,893,010 shares through centralized bidding transactions, accounting for 3.14% of the company's total share capital. The highest price of the repurchase transaction was 33.79 yuan/share, the lowest price was 27.28 yuan/share, and the total amount of capital paid was RMB 92,016,460.62 (excluding transaction fees such as stamp duty and transaction commissions).

Gelonghui FinanceApr 16 05:07 ET

Hot View Biotech (688068.SH): Proposes to acquire 100% of Kaijing Gene's shares held by an affiliated company

On April 15, Gelonghui Biotech (688068.SH) announced that in order to integrate the in-vitro diagnosis business of the company and its affiliated companies, the company plans to acquire 100% of the shares of Beijing Kaijing Gene Technology Co., Ltd. (“Kaijing Gene”) held by the affiliated company Beijing Shunjing Biomedical Technology Co., Ltd. (“Shunjing Pharmaceutical”). The transfer price for this transaction was 11 million yuan, all of which were paid in cash.

Gelonghui FinanceApr 15 05:26 ET

Hejing Biotech (688068.SH) plans to acquire 100% of Kaijing Gene's shares to integrate the in vitro diagnostic business

According to Zhitong Finance App News, Hot View Biotech (688068.SH) announced that in order to integrate the in vitro diagnosis business of the company and related companies, the company plans to acquire 100% of the shares of Beijing Kaijing Gene Technology Co., Ltd. (“Shunjing Gene”) held by the affiliated company Beijing Shunjing Biomedical Technology Co., Ltd. (“Shunjing Pharmaceutical”). The transfer price for this transaction was 11 million yuan, all of which were paid in cash. According to reports, Kaijing Gene was founded in 2016 and is a biotechnology service company specializing in R&D, production and sales of in vitro diagnostic reagent raw materials. It is proposed for in vitro diagnostic reagent manufacturers

Zhitong FinanceApr 15 05:23 ET

Hot View Biotech (688068.SH): Foreign trade is currently progressing well

Gelonghui, April 11, 丨 Hot View Biotech (688068.SH) Investor Relations Activity Record Sheet shows that the company has always insisted on placing equal emphasis on domestic and foreign markets and is actively expanding overseas markets. Currently, foreign trade is progressing well. The company has established two professional marketing management teams, international and domestic, and has set up subsidiaries in India, Hong Kong and the United States, and set up offices in Thailand to develop global business.

Gelonghui FinanceApr 11 03:49 ET

Hot View Biotech (688068.SH): A total cost of 87.02 million yuan to buy back 2.95% of the shares

Gelonghui, April 2, 丨 Hot View Biotech (688068.SH) announced that by the close of trading on March 29, 2024, the company had repurchased 2,718,010 shares through centralized bidding transactions, accounting for 2.95% of the company's total share capital, an increase of 0% compared with the previous disclosure. The highest price of the repurchase transaction was 33.79 yuan/share, the lowest price was 27.28 yuan/share, and the total amount of capital paid was RMB 87,021,704.94 (excluding transaction fees such as stamp duty and transaction fees).

Gelonghui FinanceApr 2 07:58 ET

Hot View Biotech (688068.SH): 2.95% of shares have been repurchased

Gelonghui, March 4, 丨 Hot View Biotech (688068.SH) announced that by the close of trading on February 29, 2024, the company had repurchased 2,718,000 shares through centralized bidding transactions, accounting for 2.95% of the company's total share capital, an increase of 0.27% compared with the previous disclosure. The highest price of the repurchase transaction was 33.79 yuan/share, the lowest price was 27.28 yuan/share, and the total amount of capital paid was RMB 87.0217 million (excluding transaction fees such as stamp duty and transaction fees).

Gelonghui FinanceMar 4 04:57 ET